New combo therapy aims to slow resistant prostate cancer
Disease control
Recruiting now
This study tests whether adding an experimental drug (ZEN003694) to the standard treatment enzalutamide can help men with a certain type of advanced prostate cancer that has stopped responding to another drug (abiraterone). About 200 men will be randomly assigned to receive eithe…
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 17, 2026 11:03 UTC